Solid tumors represent a formidable clinical research challenge due to many factors, including substantial intratumor heterogeneity. While these tumors have unique features that have historically made them difficult to treat, the growth in precision medicine provides new hope. This shift improves treatment outcomes but requires deliberate planning to optimize the balance between participant enrichment strategies and sufficient enrollment to produce results.
To Enrich or Not To Enrich: Breaking Barriers in Solid Tumors with Precision Medicine and Operations
Read more